Form 4: Opaleye Management Boosts CDXS Stake

Opaleye Management Inc., a 10% owner of Codexis, Inc., increased its indirect beneficial ownership of common stock through recent purchases.

Summary

• Opaleye Management Inc. reported acquiring additional common stock of Codexis, Inc. (CDXS).
• On July 31, 2025, 84,220 shares were purchased at $2.68 per share.
• On August 4, 2025, an additional 780 shares were purchased at $2.835 per share.
• These purchases were made indirectly through Opaleye, L.P.
• Following these transactions, Opaleye, L.P. beneficially owns 12,545,000 shares.
• An additional 250,000 shares are indirectly owned through a separately managed account.
• Total indirect beneficial ownership reported by Opaleye Management Inc. is 12,795,000 shares.

Sentiment

Score: 8

Explanation: The acquisition of additional shares by a 10% owner and investment manager signals strong confidence in the company's valuation and future prospects, which is a highly positive indicator for investors.

Positives

• A significant shareholder, Opaleye Management Inc., increased its stake in Codexis, Inc., indicating confidence in the company's future.
• The purchases were made at prices of $2.68 and $2.835 per share, suggesting a belief in the stock's value at these levels.

Future Outlook

The filing does not provide forward-looking statements or guidance, as it is a report of past transactions.

Management Comments

• Opaleye Management Inc. disclaims beneficial ownership of the shares reported except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Insider buying, especially by a significant shareholder like Opaleye Management, can signal confidence in the company's future prospects within the biotechnology or enzyme engineering sector. This type of activity is often viewed positively by the market, suggesting that those with deep knowledge of the company believe its stock is undervalued or poised for growth.

Comparison to Industry Standards

• This filing reports an insider purchase, which is a standard disclosure for significant shareholders. There are no specific company or project results to compare against industry benchmarks.
• Insider buying trends are generally seen as a positive indicator, aligning with the behavior of informed investors who increase their stake when they perceive value.
• For example, similar insider purchases have been observed in other biotech firms like Ginkgo Bioworks (DNA) or Zymergen (ZY) (before its acquisition), where key investors or founders increased their holdings, often preceding periods of positive performance or strategic developments.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees and management might feel validated by the significant shareholder's increased investment, potentially boosting morale.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, which primarily reports past transactions.

Key Dates

Recommendation

The significant insider buying by Opaleye Management Inc., a 10% owner, suggests strong conviction in Codexis's value proposition and future outlook. Insider purchases are often a bullish signal, indicating that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth. This action by a sophisticated investor warrants a 'buy' recommendation for investors looking for companies with strong insider confidence.

Keywords

Codexis, CDXS, Opaleye Management, Insider Buying, Form 4, Beneficial Ownership, Stock Purchase, Biotechnology, Enzyme Engineering